Clozapine prescribing for young people with treatment-resistant schizophrenia
BJPsych Advances · 2026-05 · 32 (3) · 192-203
DOI: 10.1192/bja.2025.10172 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Advances, online erschienen am 03.11.2025. Verfasst von Graham Walker und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clozapine is the only medication specifically recommended for treatment-resistant schizophrenia, but research suggests that it is universally underprescribed, particularly among children and adolescents. This article discusses clinicians’ reluctance to prescribe clozapine for all age groups, and outlines its benefits for treatment-resistant schizophrenia in young people. It summarises guidelines on clozapine therapy for adults, including initiation, monitoring and adverse and side-effects, and describes how they can be applied to a younger population. Psychiatrists who care for younger people have consistently highlighted a wish for more learning opportunities focusing on clozapine, such as the content of this article.
Zitieren
APA
Walker, G., Little, K., Haridas, M., & Krishnadas, R. (2026). Clozapine prescribing for young people with treatment-resistant schizophrenia. BJPsych Advances, 32(3), 192-203. https://doi.org/10.1192/bja.2025.10172
Vancouver
Walker G, Little K, Haridas M, Krishnadas R. Clozapine prescribing for young people with treatment-resistant schizophrenia. BJPsych Advances. 2026;32(3):192-203. doi:10.1192/bja.2025.10172
BibTeX
@article{Walker2026,
author = {Walker, Graham and Little, Kirsten and Haridas, Manju and Krishnadas, Rajeev},
title = {Clozapine prescribing for young people with treatment-resistant schizophrenia},
journal = {BJPsych Advances},
year = {2026},
volume = {32},
number = {3},
pages = {192--203},
doi = {10.1192/bja.2025.10172}
}
EUVIMED